Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 11/2023

Open Access 30-09-2023 | Omalizumab | Review

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Authors: Thomas B. Casale, Ana Maria Gimenez-Arnau, Jonathan A. Bernstein, Michael Holden, Torsten Zuberbier, Marcus Maurer

Published in: Dermatology and Therapy | Issue 11/2023

Login to get access

Abstract

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.
Literature
1.
Zuberbier T, Abdul Latiff AH, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–66.PubMedCrossRef
2.
3.
Kolkhir P, Gimenez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61.PubMedCrossRef
4.
Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547–65.PubMedCrossRef
5.
Wertenteil S, Strunk A, Garg A. Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2019;81(1):152–6.PubMedCrossRef
6.
Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869–73.PubMedCrossRef
7.
Balp MM, Weller K, Carboni V, et al. Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol. 2018;29(6):630–6.PubMedCrossRef
8.
Sanchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14(6):100533.PubMedPubMedCentralCrossRef
9.
Metz M, Altrichter S, Buttgereit T, et al. The diagnostic workup in chronic spontaneous urticaria—what to test and why. J Allergy Clin Immunol Pract. 2021;9(6):2274–83.PubMedCrossRef
10.
Stepaniuk P, Kan M, Kanani A. Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2020;16:63.PubMedPubMedCentralCrossRef
11.
Balp MM, Halliday AC, Severin T, et al. Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review. Dermatol Ther (Heidelb). 2022;12(1):15–27.PubMedCrossRef
12.
Sussman G, Abuzakouk M, Berard F, et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy. 2018;73(8):1724–34.PubMedCrossRef
13.
Zazzali JL, Kaplan A, Maurer M, et al. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol. 2016;117(4):370–7 (e371).PubMedCrossRef
14.
Champion RH, Roberts SO, Carpenter RG, Roger J. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol. 1969;81(8):588–97.PubMedCrossRef
15.
Curto-Barredo L, Archilla LR, Vives GR, Pujol RM, Gimenez-Arnau AM. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98(7):641–7.PubMedCrossRef
16.
Dobrican CT, Muntean IA, Pintea I, Petricau C, Deleanu DM, Filip GA. Immunological signature of chronic spontaneous urticaria (review). Exp Ther Med. 2022;23(6):381.PubMedPubMedCentralCrossRef
17.
Hide M, Kaplan AP. Concise update on the pathogenesis of chronic spontaneous urticaria (CSU). J Allergy Clin Immunol. 2022;150(6):1403–4.PubMedCrossRef
18.
Kaplan A, Lebwohl M, Gimenez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389–401.PubMedCrossRef
19.
Jang JH, Moon J, Yang EM, et al. Detection of serum IgG autoantibodies to FcεRIα by ELISA in patients with chronic spontaneous urticaria. PLoS One. 2022;17(8):e0273415.PubMedPubMedCentralCrossRef
20.
Hennino A, Berard F, Guillot I, Saad N, Rozieres A, Nicolas JF. Pathophysiology of urticaria. Clin Rev Allergy Immunol. 2006;30(1):3–11.PubMedCrossRef
21.
Kolkhir P, Munoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819–31.PubMedCrossRef
22.
Xiang YK, Kolkhir P, Scheffel J, et al. Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa. J Allergy Clin Immunol Pract. 2023:S2213-2198(2223)00184-00188.
23.
Asero R, Ferrer M, Kocaturk E, Maurer M. Chronic spontaneous urticaria: the role and relevance of autoreactivity, autoimmunity, and autoallergy. J Allergy Clin Immunol Pract. 2023:S2213–2198(2223)00226-X.
24.
Ansotegui IJ, Bernstein JA, Canonica GW, et al. Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride. Allergy Asthma Clin Immunol. 2022;18(1):41.PubMedPubMedCentralCrossRef
25.
Nettis E, Foti C, Ambrifi M, et al. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clin Mol Allergy. 2020;18:8.PubMedPubMedCentralCrossRef
26.
Giménez-Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9(6):2195–208.PubMedCrossRef
27.
28.
Goncalo M, Gimenez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226–36.PubMedCrossRef
29.
O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197–201.PubMedCrossRef
30.
Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol. 2015;115(4):306–11.PubMedCrossRef
31.
Yun J, Katelaris CH, Weerasinghe A, Adikari DB, Ratnayake C. Impact of chronic urticaria on the quality of life in Australian and Sri Lankan populations. Asia Pac Allergy. 2011;1(1):25–9.PubMedPubMedCentralCrossRef
32.
Ertas R, Erol K, Hawro T, Yilmaz H, Maurer M. Sexual functioning is frequently and markedly impaired in female patients with chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2020;8(3):1074–82.PubMedCrossRef
33.
Maxim E, Aksut C, Tsoi D, Dellavalle R. Global burden of urticaria: insights from the 2016 Global Burden of Disease Study. J Am Acad Dermatol. 2018;79(3):567–9.PubMedPubMedCentralCrossRef
34.
Maurer M, Abuzakouk M, Berard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–16.PubMedCrossRef
35.
Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy. 2013;68(2):131–41.PubMedCrossRef
36.
Engin B, Uguz F, Yilmaz E, Ozdemir M, Mevlitoglu I. The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol. 2008;22(1):36–40.PubMedCrossRef
37.
38.
Staubach P, Dechene M, Metz M, et al. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011;91(5):557–61.PubMedCrossRef
39.
Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154(2):294–8.PubMedCrossRef
40.
Huang Y, Xiao Y, Jing D, et al. Association of chronic spontaneous urticaria with anxiety and depression in adolescents: a mediation analysis. Front Psychiatry. 2021;12:655802.PubMedPubMedCentralCrossRef
41.
42.
43.
Agondi RC, Argolo PN, Mousinho-Fernandes M, Gehlen B, Kalil J, Motta AA. Multiple comorbidities in patients with long-lasting chronic spontaneous urticaria. An Bras Dermatol. 2023;98(1):93–6.PubMedCrossRef
44.
Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev. 2017;16(12):1196–208.PubMedCrossRef
45.
Goldstein S, Eftekhari S, Mitchell L, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99(12):1091–8.PubMed
46.
Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152(2):289–95.PubMedCrossRef
47.
Mendelson MH, Bernstein JA, Gabriel S, et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. J Dermatol Treat. 2017;28(3):229–36.CrossRef
48.
Wagner N, Zink A, Hell K, et al. Patients with chronic urticaria remain largely undertreated: results from the DERMLINE online survey. Dermatol Ther (Heidelb). 2021;11(3):1027–39.PubMedCrossRef
49.
Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it’s worse than we thought—first results of the multicenter real-life AWARE study. Clin Exp Allergy. 2017;47(5):684–92.PubMedCrossRef
50.
Kolkhir P, Pogorelov D, Darlenski R, et al. Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organ J. 2018;11(1):14.PubMedPubMedCentralCrossRef
51.
Zuberbier T, Bernstein JA, Maurer M. Chronic spontaneous urticaria guidelines: what is new? J Allergy Clin Immunol. 2022;150(6):1249–55.PubMedCrossRef
52.
Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–49.PubMedCrossRef
53.
Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Br J Dermatol. 2021;184(1):167–8.PubMedCrossRef
54.
Gimenez-Arnau AM, Ribas-Llaurado C, Mohammad-Porras N, Deza G, Pujol RM, Gimeno R. IgE and high-affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance. Clin Transl Allergy. 2022;12(2): e12117.PubMedPubMedCentralCrossRef
55.
Genentech. Xolair prescribing information. Genentech; 2021.
56.
Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623–32.PubMedCrossRef
57.
Mankad VS, Burks AW. Omalizumab: other indications and unanswered questions. Clin Rev Allergy Immunol. 2005;29(1):17–30.PubMedCrossRef
58.
Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol Pract. 2004;114(3):465–74.CrossRef
59.
Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol Pract. 2011;128(1):202–9 (e205).CrossRef
60.
Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin. Theranostics. 2017;7(5):1266–76.PubMedPubMedCentralCrossRef
61.
Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519–33.PubMedCrossRef
62.
Ozaydin-Yavuz G, Yavuz IH, Inaloz HS, Boyvadoglu C. Omalizumab is not just an anti-immunoglobulin E. J Dermatol Treat. 2022;33:2858–61.CrossRef
63.
Zhou B, Li J, Liu R, Zhu L, Peng C. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria. Front Immunol. 2022;13: 879754.PubMedPubMedCentralCrossRef
64.
Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139(3):1059–61 (e1051).PubMedCrossRef
65.
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–9.PubMedCrossRef
66.
Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–35.PubMedCrossRef
67.
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(3):925.PubMedCrossRef
68.
Giménez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017;17(3):375–85.PubMedCrossRef
69.
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–50 (e1744).PubMedCrossRef
70.
Dekkers C, Alizadeh Aghdam M, de Graaf M, et al. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatr Allergy Immunol. 2021;32(4):720–6.PubMedPubMedCentralCrossRef
71.
Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. 2020;37(6):1051–4.PubMedCrossRef
72.
Ocak M, Soyer O, Buyuktiryaki B, Sekerel BE, Sahiner UM. Omalizumab treatment in adolescents with chronic spontaneous urticaria: efficacy and safety. Allergol Immunopathol (Madr). 2020;48(4):368–73.PubMedCrossRef
73.
Song XT, Chen YD, Yu M, Liu B, Zhao ZT, Maurer M. Omalizumab in children and adolescents with chronic urticaria: a 16-week real-world study. Allergy. 2021;76(4):1271–3.PubMedCrossRef
74.
Martina E, Damiani G, Grieco T, Foti C, Pigatto PDM, Offidani A. It is never too late to treat chronic spontaneous urticaria with omalizumab: real-life data from a multicenter observational study focusing on elderly patients. Dermatol Ther. 2021;34(2):e14841.PubMedCrossRef
75.
Sirufo MM, Bassino EM, De Pietro F, Ginaldi L, De Martinis M. Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria. Int J Immunopathol Pharmacol. 2021;35:20587384211065870.PubMedCrossRef
76.
Hide M, Park HS, Igarashi A, et al. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. J Dermatol Sci. 2017;87(1):70–8.PubMedCrossRef
77.
Skander D, Allenova A, Maurer M, Kolkhir P. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. Eur Ann Allergy Clin Immunol. 2021;53(2):91–3.PubMedCrossRef
78.
Gonzalez-Medina M, Curto-Barredo L, Labrador-Horrillo M, Gimenez-Arnau A. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol. 2017;31(5):e245–6.PubMedCrossRef
79.
Turk M, Carneiro-Leao L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113–24.PubMedCrossRef
80.
Berard F, Ferrier Le Bouedec MC, Bouillet L, et al. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study. Br J Dermatol. 2019;180(1):56–66.PubMedCrossRef
81.
Finlay AY, Kaplan AP, Beck LA, et al. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017;31(10):1715–21.PubMedPubMedCentralCrossRef
82.
Gimenez-Arnau AM, Spector S, Antonova E, et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clin Transl Allergy. 2016;6:32.PubMedPubMedCentralCrossRef
83.
Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017;31(6):1056–63.PubMedPubMedCentralCrossRef
84.
Durmaz K, Ataseven A, Temiz SA, Isik B, Dursun R. Does omalizumab use in chronic spontaneous urticaria results in improvement in sexual functions? J Cosmet Dermatol. 2022;21(10):4877–81.PubMedCrossRef
85.
Casale TB, Murphy TR, Holden M, Rajput Y, Yoo B, Bernstein JA. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: results from a randomized study (XTEND-CIU). J Allergy Clin Immunol Pract. 2019;7(7):2487–90 (e2481).PubMedCrossRef
86.
Casale TB, Win PH, Bernstein JA, et al. Omalizumab response in patients with chronic idiopathic urticaria: insights from the XTEND-CIU study. J Am Acad Dermatol. 2018;78(4):793–5.PubMedCrossRef
87.
Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1-antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135–44.PubMedCrossRef
88.
Goswamy VP, Lee KE, McKernan EM, Fichtinger PS, Mathur SK, Viswanathan RK. Omalizumab for treatment of idiopathic angioedema. Ann Allergy Asthma Immunol. 2022;129(5):605–11 (e601).PubMedCrossRef
89.
Porter E, Tierney E, Byrne B, et al. “It has given me my life back”: a qualitative study exploring the lived experience of patients with chronic spontaneous urticaria on omalizumab. Clin Exp Dermatol. 2022;47(11):2032–4.PubMedCrossRef
90.
Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474–81.PubMedCrossRef
91.
Syrigos N, Grapsa D, Zande M, Tziotou M, Syrigou E. Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria. Int J Dermatol. 2018;57(4):417–22.PubMedCrossRef
92.
Gimenez Arnau AM, Valero Santiago A, Bartra Tomas J, et al. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria. J Investig Allergol Clin Immunol. 2019;29(5):338–48.PubMedCrossRef
93.
Metz M, Vadasz Z, Kocaturk E, Gimenez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45.PubMedPubMedCentralCrossRef
94.
Bras R, Costa C, Limao R, Caldeira LE, Paulino M, Pedro E. Omalizumab in CSU: real-life experience in doses/intervals adjustments and treatment discontinuation. J Allergy Clin Immunol Pract. 2023;S2213–2198(2223):00093–4.
95.
Di Bona D, Nettis E, Bilancia M, et al. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: a long-term observational study. J Allergy Clin Immunol Pract. 2021;9(6):2482–5 (e2482).PubMedCrossRef
96.
Ferrer M, Gimenez-Arnau A, Saldana D, et al. Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis. J Allergy Clin Immunol Pract. 2018;6(4):1191–7 (e1195).PubMedCrossRef
97.
Sussman G, Hebert J, Gulliver W, et al. Omalizumab re-treatment and step-up in patients with chronic spontaneous urticaria: OPTIMA trial. J Allergy Clin Immunol Pract. 2020;8(7):2372–8 (e2375).PubMedCrossRef
98.
Salman A, Aktas M, Apti SO. Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: real-life data. Australas J Dermatol. 2021;62(3):398–402.PubMedCrossRef
99.
Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705–12.PubMedCrossRef
100.
Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76(10):2965–81.PubMedCrossRef
101.
Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2019;33(5):918–24.PubMedCrossRef
102.
Straesser MD, Oliver E, Palacios T, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1386–8 (e1381).PubMedCrossRef
103.
Weller K, Ohanyan T, Hawro T, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73(12):2406–8.PubMedCrossRef
104.
Yu M, Terhorst-Molawi D, Altrichter S, et al. Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response. Clin Exp Allergy. 2021;51(5):730–4.PubMedCrossRef
105.
Ghazanfar MN, Bartko EA, Arildsen NS, et al. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: a three-month prospective study. Clin Exp Allergy. 2022;52(5):715–8.PubMedPubMedCentralCrossRef
106.
Deza G, Bertolin-Colilla M, Sanchez S, et al. Basophil FcvarepsilonRI expression is linked to time to omalizumab response in chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;141(6):2313–6 (e2311).PubMedCrossRef
107.
Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract. 2020;8(1):318–25 (e315).PubMedCrossRef
108.
Ertas R, Hawro T, Altrichter S, et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy. 2020;75(2):468–70.PubMedCrossRef
109.
Palacios T, Stillman L, Borish L, Lawrence M. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016;4(3):529–30.PubMedCrossRef
110.
Cakmak ME. Comparison of the patients with chronic urticaria who responded and did not respond to omalizumab treatment: a single-center retrospective study. Int Arch Allergy Immunol. 2022;183(11):1209–15.PubMedCrossRef
111.
Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;140(6):1749–51.PubMedCrossRef
112.
Lowe PJ, Georgiou P, Canvin J. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. Regul Toxicol Pharmacol. 2015;71(1):68–77.PubMedCrossRef
113.
Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1: CD003559.
114.
Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2019;155(1):29–38.PubMedCrossRef
115.
Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study. Respir Med. 2017;130:55–60.PubMedCrossRef
116.
Harrison RG, MacRae M, Karsh J, Santucci S, Yang WH. Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience. Ann Allergy Asthma Immunol. 2015;115(1):77–8.PubMedCrossRef
117.
Gulsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int. 2020;29(4):97–125.PubMedPubMedCentralCrossRef
118.
Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clin Transl Allergy. 2021;11(4): e12038.PubMedPubMedCentralCrossRef
119.
Tanno LK, Demoly P. Biologicals for the prevention of anaphylaxis. Curr Opin Allergy Clin Immunol. 2021;21(3):303–8.PubMedCrossRef
120.
Kocaturk E, Salman A, Cherrez-Ojeda I, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76(3):816–30.PubMedCrossRef
121.
Klimek L, Pfaar O, Worm M, et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: position paper of Arzteverband Deutscher Allergologen (AeDA)(A), Deutsche Gesellschaft fur Allergologie und Klinische Immunologie (DGAKI)(B), Gesellschaft fur Padiatrische Allergologie und Umweltmedizin (GPA)(C), Osterreichische Gesellschaft fur Allergologie und Immunologie (OGAI)(D), Luxemburgische Gesellschaft fur Allergologie und Immunologie (LGAI)(E), Osterreichische Gesellschaft fur Pneumologie (OGP)(F) in co-operation with the German, Austrian, and Swiss ARIA groups(G), and the European Academy of Allergy and Clinical Immunology (EAACI)(H). Allergol Select. 2020;4:53–68.PubMedPubMedCentralCrossRef
122.
Ghiglioni DG, Cozzi EL, Castagnoli R, et al. Omalizumab may protect allergic patients against COVID-19: a systematic review. World Allergy Organ J. 2023;16(2):100741.PubMedPubMedCentralCrossRef
123.
Atayik E, Aytekin G. The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment. Rev Fr Allergol (2009). 2022;62(8):684–8.PubMedCrossRef
124.
Bostan E, Yalici-Armagan B, Gokoz O. Chronic urticaria may not be as innocent as we think: a rare case of acquired cutis laxa following chronic urticaria. J Cosmet Dermatol. 2022;21(7):3154–6.PubMedCrossRef
125.
Kulu H, Atasoy M, Ozyurt K, et al. The COVID-19 pandemic affects male patients with chronic spontaneous urticaria more than female patients. Front Immunol. 2021;12:722406.PubMedPubMedCentralCrossRef
126.
King C, Cox F, Sloan A, McCrea P, Edgar JD, Conlon N. Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: a patient perspective. World Allergy Organ J. 2021;14(10): 100587.PubMedPubMedCentralCrossRef
127.
Grieco T, Ambrosio L, Trovato F, et al. Effects of vaccination against COVID-19 in chronic spontaneous and inducible urticaria (CSU/CIU) patients: a monocentric study. J Clin Med. 2022;11(7):1822.PubMedPubMedCentralCrossRef
128.
Smola A, Samadzadeh S, Muller L, et al. Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(11):e743–5.PubMedPubMedCentralCrossRef
129.
Denman S, Ford K, Toolan J, et al. Home self-administration of omalizumab for chronic spontaneous urticaria. Br J Dermatol. 2016;175(6):1405–7.PubMedCrossRef
130.
Menzella F, Ferrari E, Ferrucci SM, et al. Self-administration of omalizumab: why not? A literature review and expert opinion. Expert Opin Biol Ther. 2021;21(4):499–507.PubMedCrossRef
131.
Murphy KR, Winders T, Smith B, Millette L, Chipps B. Identifying patients for self-administration of omalizumab. Adv Ther. 2023;40(1):19–24.PubMedCrossRef
132.
Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old. Allergy. 2022;77(1):17–38.PubMedCrossRef
133.
Koç Yildirim S, Erbağci E, Hapa A. Omalizumab treatment in combination with any other biologics: is it really a safe duo? Australas J Dermatol. 2023;64(2):229–33.PubMedCrossRef
134.
Namazy J, Scheuerle AE, Spain V, et al. Pregnancy and infant outcomes among pregnant women with chronic spontaneous urticaria (CSU) treated with omalizumab: a descriptive analysis from the EXPECT pregnancy registry. Presented virtually at the American Academy of Allergy, Asthma & Immunology | 26 February – March 1, 2021.
135.
Mosnaim GS, Greenhawt M, Imas P, et al. Do regional geography and race influence management of chronic spontaneous urticaria? J Allergy Clin Immunol. 2022;150(6):1260–4 (e1267).PubMedCrossRef
136.
Zhang Y, Zhang H, Du S, Yan S, Zeng J. Advanced biomarkers: therapeutic and diagnostic targets in urticaria. Int Arch Allergy Immunol. 2021;182(10):917–31.PubMedCrossRef
137.
Deza G, Ricketti PA, Gimenez-Arnau AM, Casale TB. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1108–17.PubMedCrossRef
138.
Greiner B, Nicks S, Adame M, McCracken J. Pathophysiology, diagnosis, and management of chronic spontaneous urticaria: a literature review. Clin Rev Allergy Immunol. 2022;63(3):381–9.PubMedCrossRef
139.
Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. 2021;9(3):1067–78.PubMedCrossRef
140.
141.
Metadata
Title
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
Authors
Thomas B. Casale
Ana Maria Gimenez-Arnau
Jonathan A. Bernstein
Michael Holden
Torsten Zuberbier
Marcus Maurer
Publication date
30-09-2023
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 11/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-023-01040-9

Other articles of this Issue 11/2023

Dermatology and Therapy 11/2023 Go to the issue

Original Research

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry

Correction

Correction to: Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study

Review

Treatments for Dissecting Cellulitis of the Scalp: A Systematic Review and Treatment Algorithm

Brief Report

Responsiveness and Minimal Clinically Important Difference of the Infants and Toddlers Dermatology Quality of Life Questionnaire

Brief Report

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

Letter

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits